Sage Journals: Discover world-class research

Abstract

Background

Medication-overuse headache leads to high disability and decreased quality of life, and the best approach for withdrawal has been debated.

Aim

To compare change in disability and quality of life between two withdrawal programs.

Methods

We randomized medication-overuse headache patients to program A (two months without acute analgesics or migraine medications) or program B (two months with acute medications restricted to two days/week) in a prospective, outpatient study. At 6 and 12 months, we measured disability and headache burden by the Headache Under-Response to Treatment index (HURT). We estimated quality of life by EUROHIS-QOL 8-item at 2-, 6-, and 12-month follow-up. Primary endpoint was disability change at 12 months.

Results

We included 72 medication-overuse headache patients with primary migraine and/or tension-type headache. Fifty nine completed withdrawal and 54 completed 12-month follow-up. At 12-month follow-up, 41 patients completed HURT and 38 completed EUROHIS-QOL 8-item. Disability reduction was 25% in program-A and 7% in program-B (p = 0.027). Headache-burden reduction was 33% in program-A and 3% in program-B (p = 0.005). Quality of life was increased by 8% in both programs without significant difference between the programs (p = 0.30). At 2-month follow-up, quality of life increased significantly more in program-A than program-B (p = 0.006).

Conclusion

Both withdrawal programs reduced disability and increased quality of life. Withdrawal without acute medication was the most effective in reducing disability in medication-overuse headache patients.

Trial registration

Clinicaltrials.gov (NCT02903329).

Keywords

Medication-overuse restricted medication-intake detoxification disability quality of life

Introduction

Medication-overuse headache (MOH) is a condition, where intake of symptomatic medication for headache may paradoxically lead to a worsening of headache (1). It affects 1–2% of the general population worldwide and 30–50% of patients in specialized headache centres. Medication overuse is associated with chronification of headache, especially migraine (2,3).

The recommended treatment of MOH is to cease the overuse (1,3), and withdrawal has demonstrated to revert at least half of patients to episodic headache (4,5). There is a lack of international consensus on withdrawal strategies. However, it is agreed that advice and patient education should be an essential first part of a treatment program (1,6,7). Most international treatment programs use restricted withdrawal, which means a certain decrease in frequency in monthly medication intake, often combined with medical preventives (5,6,8). Complete stop of acute medication combined with rescue medication, patient education, and close follow-up is recommended in current Danish guidelines, a procedure supported by several studies (4,9 –11). Recently, Carlsen et al. demonstrated that withdrawal without any analgesics or acute migraine medication was more effective than restricted withdrawal with acute medications and/or analgesics up to two days/week regarding reduction of headache days and hereby number of patients reverting to episodic headache (4). Disability and quality of life, which also are very important end-points, were measured but not analyzed in that part of the study (4). It has been suggested that MOH has negative impact on disability and quality of life (12 –15) which to some extent are improved when the overuse is treated (15 –19).

The aim of the study was to examine whether change in disability and quality of life differed between a withdrawal program with complete stop of acute medications and a program that allowed restricted intake of analgesics. We hypothesized that the program with complete stop would reduce disability and headache burden more, but that the program with restricted intake had a better chance in improvement of quality of life, especially in the first two months, based on the more gradual approach with fewer withdrawal symptoms.

Methods

Study design

The present study was a predefined part of a larger study with the primary aim of comparing two withdrawal programs regarding percentage reduction in headache days/month (4). It was a randomized, prospective, longitudinal, open-label, controlled study. Patients with MOH were randomized to either treatment program A or B, both with a withdrawal period of 2 months with 12 months follow-up. In program A, patients underwent withdrawal without any analgesics or acute migraine medication. In program B, the intake was restricted, allowing patients to continue with their usual acute analgesics and/or migraine medication up to two days/week during the withdrawal. All patients were requested to continuously register headache and medication use in a standardized headache calendar. Both A and B were outpatient programs with the same patient education and follow-up visits, managed by a multidisciplinary team, and a more detailed description of the protocol has already been published (4). Patients were asked to complete the Headache Under Response to Treatment (HURT) and EUROHIS WHO Quality of Life 8-item (QOL-8) index at baseline, 6- and 12 months after withdrawal. In addition, the QOL-8 index was required at 2 months.

Study population

The study population was patients with MOH referred to the Danish Headache Center (DHC) included consecutively from October 2013 to March 2016. All participants signed informed consent. The inclusion criteria were confirmed MOH based on the ICHD-3 beta (which has same diagnostic criteria for MOH as the ICHD-3), previous diagnosis of a primary headache (chronic migraine (CM), episodic migraine (EM) and/or tension-type headache (TTH)) and being eligible for outpatient treatment (not needing in-patient care) (4). Patients had to register days with any headache for one month in a headache diary prior to the visit, and a headache specialist diagnosed MOH based on a detailed history of three months at minimum. In addition, patients had to complete the respective withdrawal strategy and fill out the questionnaires to be included in the present study.

Exclusion criteria were having a current substantial psychiatric disorder, such as schizophrenia or severe depression (the latter means a need for anti-depressive medication, treatment by a psychiatrist or treatment in a psychiatric department) or physical disorder (e.g. concomitant heart disease, severe co-morbid pain, or cancer), being previously diagnosed with another secondary headache other than MOH, being pregnant or breast feeding, or having inadequate language skills (requiring an interpreter). The study was approved by the Regional Ethical Committee in Denmark (H-1-2012-116).

Randomization

Patients were randomized to either program A or B in blocks of 10 by use of opaque, sealed envelopes as previously described (4).

Headache Under-Response to Treatment (HURT)

The Headache Under-Response to Treatment (HURT) index consists of eight items (Table 1) and has been demonstrated to be valid in headache disorders inclusive MOH (20 –24). It has been suggested that all eight questions together, also referred to as HURT-8, reflect overall clinical outcome as it combines several aspects of care and is suggested to fill a gap that no other single instrument has the capacity of (21,24). In the present study, HURT-8 was used for estimating disability. The first three questions, HURT-3, concern headache frequency over the last month and headache burden over the three last months, and was used for estimating headache burden. HURT was not measured at 2-month follow-up because some of the questions refer to the last three months, thereby including a month prior to the withdrawal (Table 1).

Table 1.

Headache Under-Response to Treatment Questionnaire (HURT) scoring system.

Nr.	Question	Option one	Option two	Option three	Option four	Option five
1.	On how many days in the last month did you have a headache?	0	0	0	2	3
2.	On how many days in the last three months did your headaches make it hard to work, study or carry out household work?	0	1	2	3	3
3.	On how many days in the last three months did your headaches spoil or prevent your family, social or leisure activities?	0	1	2	3	3
4.	On how many days in the last month did you take medication to relieve a headache? (Do not count preventive medication.)	0	0	1	2	3
5.	When you take your headache medication, does one dose get rid of your headache and keep it away?	0	0	1	2	3
6.	Do you feel in control of your headaches?	0	0	3	3	3
7.	Do you avoid or delay taking your headache medication because you do not like its side effects?	0	0	1	2	3
8.	What have you been told is your diagnosis? Do you understand this diagnosis?				Answer and Yes = 0	No or none = 3

HURT-3: The sum of scores for the first three questions (min 0, max 9). HURT-8: The sum of scores for all 8 questions (min 0, max 24).

A Danish version translated according to an official translation protocol (made by Lifting The Burden) was accessible. The options for responses to questions 1 to 7 were either number of days or a “time aspect”. Question 8 was dichotomous, and non-response as well as lack of description of diagnosis, were considered a “no”. The options were later transformed to numerical data ranging from 0 to 3, which is in accordance with the official HURT Score guideline (Table 1) (24). The score for HURT-3 ranges from 0 to 9 and HURT-8 from 0 to 24. A high value indicates severe headache burden (HURT-3) or disability (HURT-8).

EUROHIS WHO Quality of Life 8-item (QOL-8)

QOL-8 is a systematic and validated shortened version of the 26-item The World Health Organization Quality of Life (WHOQOL)-BREF (25 –27). The questionnaire comprises eight items: Two general items; overall quality of life rating and general health satisfaction, and six items that relate to the last 4 weeks. These are: Ability to perform daily life activities, patient's self-esteem, relationships, satisfaction with housing level, daily energy, and finances to handle daily necessities. Each question has 5 options of responses, for instance from “not at all” to “completely”. According to EUROHIS, the response of an item is transformed to a scale ranging from 1–5 points, where each subscale is scored positively. The eight items are then summed to a QOL-8 score (ranging from 8–40), with higher scores indicating increased quality of life (26,28).

Endpoints

The primary outcome of the present study was comparison of changes in HURT-8 score in the two programs from baseline to 12 months follow-up. Secondary outcomes regarding HURT were changes in HURT-8 from baseline to 6 months and changes in HURT-3 from baseline to 6 and 12 months. Last, we investigated change in QOL-8 from baseline to 2, 6, and 12 months' follow-up in total and for comparison between program A and B.

Statistics

Statistical calculations were performed using Rstudio for Mac, and the level of significance was set at p < 0.05. HURT and QOL-8 were transformed to numerical data according to the guidelines of each questionnaire. Continuous variables were presented as mean with SEM or 95% CI. Student's t-test was used for paired analysis on continuous variables following a normal distribution. When comparing program A and B, regarding continuous data, we used analysis of covariance (ANCOVA), which can adjust for baseline values. Categorical variables were presented as percentage and number and analysed by Fischer's exact test (for fewer than five samples).

Results

Study population

Seventy-two patients out of 553 screened patients were included (Figure 1). Thirty-five patients were randomized to program A and 37 to program B. In total, 59 patients (82%) completed 2 months withdrawal with a similar number of drop-outs in both programs at 2 months (Figure 1). Fifty-four patients (75%) attended the 12 months follow-up. Forty-one (69%) had followed the withdrawal approach and completed HURT at 12 months, and 38 patients (64%) completed QOL-8 at 12-month follow-up (Figure 1).

Figure 1.

Flowchart for the study population.¹ Need for interpretation assistance (n = 17); severe psychiatric or physical co-morbidities (n = 55); secondary headache from other than MOH (n = 9); unclear headache diagnosis (n = 9). ²Protocol A: One patient had surgery, two continued analgesics once or twice a week. Protocol B: One patient had surgery, and two needed daily analgesics without any specific reason. ³Patients did not show up for the 2 months' control visit and thereby were lost to follow-up. ⁴Protocol A: All patients with successful detoxification did not take any migraine medication or analgesics for two months, except two patients who respectively had 1 and 4 days with acute medication. ⁵Patients in brackets are those who answered QOL question 1 (Q1) at the respective month. ⁶Protocol B: One patient dropped out because of pregnancy. ⁷Protocol A: One patient dropped out because of pregnancy and one was lost to follow-up. Protocol B: One patient emigrated from Denmark, and two were lost to follow-up.

Baseline characteristics for all completers were comparable in age, gender, headache days/month, and days with acute medication/month between the two programs (Table 2). Patients in program A had approximately 1.5 years longer overuse and reported non-severe comorbidity more, and in program B more patients did not work and lived alone (Table 2). In addition, HURT-3 and -8 were comparable between the programs, but a difference between program A and B in QOL-8 at baseline was noticed (28.11 vs. 23.69, p = 0.02).

Table 2.

Baseline characteristics.

	Completers of HURT at 6 months		Completers of HURT at 12 months		Completers of QOL at 12 months
	A	B	A	B	A	B
N¹	27	25	23	18	19	16
Age (years)	46.2 (2.2)	47.8 (2.0)	47.4 (2.4)	47.7 (2.2)	48.8 (2.7)	46.6 (2.3)
Gender (female)	21 (78%)	19 (76%)	18 (78%)	13 (72%)	15 (79%)	12 (75%)
Headache days/month	24.9 (1.2)	25.5 (1.2)	24.7 (1.3)	24.9 (1.5)	25 (1.5)	26.2 (1.4)
Duration of medication overuse (years)	3.8 (1.0)	2.7 (0.4)	4 (1.2)	2.6 (0.4)	4.1 (1.4)	2.5 (0.4)
Days with acute medication/month²	21.4 (1.4)	23 (1.2)	21 (1.5)	22.2 (1.5)	20.9 (1.6)	22.9 (1.6)
Physical/psychological comorbidity (mild to moderate degree)	20 (74%)	13 (52%)	18 (78%)	7 (39%)	15 (79%)	7 (44%)
Work status
Education or full-time job	18 (66%)	12 (48%)	16 (70%)	11 (61%)	13 (68%)	9 (56%)
Education or work (full time, part time, reduced time)	22 (82%)	12 (48%)	19 (83%)	11 (61%)	15 (79%)	9 (56%)
Not working (retired, sick leave, economic support by the state)	5 (19%)	13 (52%)	4 (17%)	7 (39%)	4 (21%)	7 (44%)
Social status
Cohabitants	23 (85%)	17 (68%)	19 (83%)	13 (71%)	16 (84%)	11 (69%)
Live alone	2 (7%)	6 (24%)	2 (9%)	3 (17%)	2 (11%)	3 (19%)
Live alone with child	2 (7%)	2 (8%)	2 (9%)	1 (11%)	1 (5%)	2 (13%)

Age, headache days/month, duration of medication overuse, and days with acute medications/month are presented as mean (SEM). Gender, comorbidities, work status and social status are presented as N (%). A: Program A complete withdrawal for 2 months. B: Program B restricted intake of acute medication for 2 months. ¹Number corresponds to the number of patients answering either HURT or QOL until 12 months (column 2 and 3 respectively) and 6 months for HURT (column 1). ²Severe physical and/ or psychological comorbidities were exclusion criteria.

Baseline characteristics for patients not completing the study and/or questionnaires and for all included patients are presented in Supplemental Table 1. The number of non-completers was, for HURT, 12 in program A and 19 in program B and, for QOL-8, 16 in program A and 21 in program B. Non-completers were comparable with completers in headache frequency and number of days with acute medication intake.

Disability and headache burden

Outcomes 12 months follow-up

The reduction in HURT-8 was significantly higher in program A (from 16.7 to 12.6 corresponding to 25% reduction) than program B (from 17.1 to 15.9 corresponding to 7 % reduction) (p = 0.027) (Figure 2). Compared to baseline, HURT-8 was also reduced significantly more in program A (p < 0.001), but not in program B (p = 0.25) (Figure 2, Table 3).

Figure 2.

Scores for HURT-8 at 12 months presented as mean and SEM. n = 23 in program A with complete withdrawal vs. n = 18 in program B with restricted intake. Paired comparisons from baseline to 12 months' follow-up were made for program A and program B, as well as unpaired comparison between program A and B after 12 months.

Table 3.

HURT scores and QOL score.

		Completing questionnaire until 6 months			Completing questionnaire all 12 months
		Baseline	6 months	p-values	Baseline	12 months	p-values
HURT-3¹	Program A	6.7 (0.4)	5.2 (0.5)	0.005	6.5 (0.4)	4.3 (0.6)	< 0.001
Program B	7.3 (0.4)	6.6 (0.5)	0.086	7.1 (0.5)	6.8 (0.5)	0.68
HURT-8¹	Program A	16.9 (0.6)	13.4 (0.9)	< 0.001	16.7 (0.7)	12.6 (1.1)	< 0.001
Program B	17.4 (0.6)	16.0 (0.6)	0.072	17.1 (0.8)	15.9 (0.9)	0.25
QOL-8²	Program A	27.6 (1.1)	30.1 (1.3)	0.082	28.1 (1.1)	30.4 (1.0)	0.037
Program B	23.9 (1.2)	23.0 (1.6)	0.37	23.7 (1.3)	25.7 (1.6)	0.096

All data are presented as mean (SEM). ¹For HURT: n = 27 (program A), n = 25 (program B) at 6 months and n = 23 (program A), n = 18 (program B) at 12 months, which corresponds to the number of patients answering HURT at the respective month. ²For QOL-8: n = 21 (program A), n = 19 (program B) at 6 months and n = 19 (program A), n = 16 (program B) at 12 months, which corresponds to the number of patients answering QOL-8 at the respective month. Figures in bold: p<0.05 is considered significant and indicates significant difference from baseline to 6 or 12 months for the respective program.

In program A, HURT-3, reflecting headache burden, was reduced by 33% from baseline to 12 months and there was a trend towards reduction by 3% in program B (Table 3). The reduction in HURT-3 was significantly higher in program A than B (p = 0.005).

Outcomes 6 months follow-up

In program A, HURT-8 was reduced from 16.9 to 13.4 (p < 0.001, (95% CI 2–5)), corresponding to 21%, which was significantly more than the 8% reduction in program B (p = 0.019) (Table 3).

HURT-3 was reduced by 23% and 10% for program A and B respectively (Table 3). When comparing HURT-3 in program A and B, there was no significant difference (p = 0.12).

Quality of life

Outcomes 12 months follow-up

In program A, QOL-8 increased 2 points from 28 at baseline to 30 (p = 0.037, (95% CI −4.4 – −0.1)) and in program B, QOL-8 increased 2 points from 24 to 26 (p = 0.096), corresponding to an increase of 8% in both program A and B, with no difference between the programs (p = 0.30) (Table 3) (Figure 3).

Figure 3.

Development in QOL-8. Presented in mean score difference from baseline. Only includes patients completing all QOL-8-questionnaires (i.e. baseline, 2 months, 6 months and 12 months).

Outcomes 6 months follow-up

In total, QOL-8 increased by 2% from baseline to 6 months. This was based on an increase in program A by 7% and a reduction by 4% in program B in favour of program A at 6 months (p = 0.023) (Table 3).

Outcomes 2 months follow-up

In total, there was no change from baseline to 2 months (1%). In program A, QOL-8 increased 2 points from 27 at baseline to 29 (p = 0.018, (95% CI −3.6 – −0.4)) corresponding to an increase of 7%, while QOL-8 was reduced by 2 points from 25 to 23 (−7%) in program B (p = 0.36) (Figure 3). Between the groups, there was significant difference in favour of program A (p = 0.006). Supplemental Table 2 and 3 illustrate the results of HURT and QOL-8 without use of ANCOVA, but with Student's t-test instead.

Discussion

Main results

The main results of the present study were that disability was reduced significantly more in the program that used a complete stop of acute medications compared with the program that allowed a restricted intake of medications. The trend in the program with restricted intake was also a reduction of disability, though this was not significant (Figure 2). In addition, patients rated their quality of life equally higher at 12 months in the two programs. However, patients with a complete stop had a much faster turn-over to improved quality of life. They reported a higher score already after two months, leading to rejection of our hypothesis in favour of restricted withdrawal.

Complete withdrawal versus restricted intake

In line with the current results in this study, complete withdrawal has previously been shown to result in a significantly greater reduction of headache days/month at 6 months (46% vs. 22%) with a similar trend at 12 months (45% vs. 31%) compared to restricted intake (4). More patients also reverted to episodic headache after complete withdrawal compared with restricted intake (74 % vs. 46 % at 12 months) and migraine days/month were significantly reduced (7.8 vs. 4.6 at 12 months) (4). Regarding completion in the study by Carlsen et al., 77% in program A and 70% in program B finished the protocol at 12 months (4).

Our findings of a greater reduction in disability when initiating complete withdrawal relates to the findings of reduction in headache days/months in this study (4). This is to be expected, but it is interesting that the results only showed significance at 6 months (4) but were significant at both 6 and 12 months in our study. It can be suggested that the reduction in disability is not dependent on improvement of headache frequency alone. Reduced disability can also be due to how a headache attack is managed; for example, if the patients feel they have control over the headache, have proper treatment and can perform daily activities.

The question is why complete withdrawal seems to be the most effective treatment program in terms of both reducing headache days and disability. Concerning the reduction in disability, we suggest that it partly could be explained by an extra benefit of complete withdrawal in the form of a reinforced personal feeling of control when the medication-overuse is ceased.

And why does quality of life increase faster at a complete stop compared to restricted use? We suggest that it is a combination of faster improvement in headache frequency, the previously mentioned feeling of control, and that patients initiating a complete stop subsequently may feel better about themselves (4). At a complete stop, patients may be positively surprised that they can manage their headache without any acute medication, which may contribute to development of belief in self-efficacy and thereby higher quality of life. Self-efficacy is suggested to affect the success of MOH therapeutic strategies and high expectations of functionality in MOH patients have been addressed (12,29). On the contrary, patients with restricted intake may have had higher expectations compared to the actual profit of their treatment, reflected in decreased quality of life.

It has been addressed that MOH can cause a great individual loss for the patient, influencing education, work and private economy, but also in terms of psychological and social aspects (2). It can further be questioned how great an impact all these aspects of life have on coping opportunities and on how well the patient can adjust their life to the withdrawal program. In future studies, it could be interesting to investigate whether a patient's way of running their life can predict whether complete withdrawal or restricted intake would have the best long-term results for a specific patient.

In the study by Westergaard et al., patients with MOH at the initial visit had a mean HURT-8 score of 17.0 (24), consistent with our findings, and a HURT-8 score at the final visit of 12.5, which is almost identical to program A, while the reduction was less convincing in program B.

There are to our knowledge few studies assessing QOL in patients with MOH during a treatment intervention, and those that do exist use different questionnaires. A Russian cross-sectional study found a QOL-8 score of 24.7 (30). This is in line with program B and slightly lower than program A (Table 3), possibly explained by some national differences in aspects related to quality of life.

Strengths and drawbacks

A major strength of this randomized controlled study is the prospective long-term evaluation of the treatment programs at 12 months. The results add important new knowledge on outcome of medication withdrawal not only for headache parameters but also for disability and quality of life.

The screening of 553 patients indicates that patients with the diagnosis of MOH with migraine and/or TTH are thoroughly selected and confirmed, because patients with other secondary headaches are deselected. Yet, the number of screened patients also address the risk of selection bias as some patients did not wish to participate. In addition, some patients chose an in-patient program outside this study, though it was assessed by clinicians that the grade of severity of their condition was consistent with an outpatient approach.

It is important to notice that as it only included patients suitable for outpatient treatment based on CM, EM and/or TTH, the present study did not deal with most complicated patients needing in-patient treatment; for example, with severe comorbidities including need of psychiatric expertise, use of anti-depressant medication, overuse of opioids failing previous outpatient treatments or based on a secondary headache other than MOH. A similar study of the severely affected MOH patients on an in-patient basis could be of interest in the future.

Another limitation is the number of patients not completing all questionnaires, causing the total completion rate to decrease from approximately 70–77% (caused by dropout alone) to 64–69% when combining dropout and non-completed questionnaires. However, completers and non-completers had similar baseline characteristics with only minor unimportant differences.

Our results can support clinicians in advising MOH patients with their selection of withdrawal approach. The potential advantage of a complete stop is emphasized, and in addition patients can be reassured that this stop is not unbearable and does not lower the quality of life compared to restricted withdrawal. The outcome measure is not only based on headache frequency, and thereby the assessment of efficiency of the two programs becomes more patient-oriented and clinically relevant.

Conclusion

At 12 months, disability was improved significantly in the program with complete withdrawal compared to the program with restricted withdrawal. Both withdrawal programs improved quality of life equally, yet complete withdrawal let to a faster increase.

This study establishes the importance of withdrawal and suggests an advantage and the obtainable gain in the patient's life when the withdrawal is two months of complete stop of analgesics and acute migraine medication, together with support and close follow-up.

Supplemental Material

Supplemental material for Complete withdrawal is the most effective approach to reduce disability in patients with medication-overuse headache: A randomized controlled open-label trial

Supplemental Material1 for Complete withdrawal is the most effective approach to reduce disability in patients with medication-overuse headache: A randomized controlled open-label trial by Mia Nielsen, Louise Ninett Carlsen, Signe Bruun Munksgaard, Ida Maria Storm Engelstoft, Rigmor Højland Jensen and Lars Bendtsen in Cephalalgia

Supplemental Material

Supplemental material for Complete withdrawal is the most effective approach to reduce disability in patients with medication-overuse headache: A randomized controlled open-label trial

Supplemental Material2 for Complete withdrawal is the most effective approach to reduce disability in patients with medication-overuse headache: A randomized controlled open-label trial by Mia Nielsen, Louise Ninett Carlsen, Signe Bruun Munksgaard, Ida Maria Storm Engelstoft, Rigmor Højland Jensen and Lars Bendtsen in Cephalalgia

Supplemental Material

Supplemental material for Complete withdrawal is the most effective approach to reduce disability in patients with medication-overuse headache: A randomized controlled open-label trial

Supplemental Material3 for Complete withdrawal is the most effective approach to reduce disability in patients with medication-overuse headache: A randomized controlled open-label trial by Mia Nielsen, Louise Ninett Carlsen, Signe Bruun Munksgaard, Ida Maria Storm Engelstoft, Rigmor Højland Jensen and Lars Bendtsen in Cephalalgia

Footnotes

Clinical implications

Complete stop of acute medication is the most effective method to reduce headache burden and disability.

Withdrawal improves quality of life in MOH patients and a complete stop of medication shortens the time to improvement.

Acknowledgements

The authors thank the headache nurses Malene Kjærgaard Danø, Annette Vangaa Rasmussen, Hjørdis Rasmussen and Annette Fjeldborg Jonasson for planning and management of the patient education program and collecting of data. Additionally, we thank project nurse Mette Frank Fisker for data management and data typing.

Declaration of conflicting interests

The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: SB Munksgaard has undertaken lectures for Berlin-Chemie and UCB. RH Jensen has participated in clinical trials for ATI, Electrocore, Eli-Lilly and Linde Gas Ltd., and is a director of LTB, trustee of IHS and past president of EHF, and has the following additional disclosures: Lectures for Pfizer, Berlin-Chemie, Allergan, Merck, and ATI. L Bendtsen has the following disclosures: Advisory board member for Allergan, Novartis and Biogen. M Nielsen, LN Carlsen and IMS Engelstoft have nothing to declare.

Funding

The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: M Nielsen has received a 6-month scholarship from the Danish Medical Society Copenhagen (DMSK). LN Carlsen, SB Munksgaard, and R Jensen have received funding from the TrygFoundation.

References

Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia 2018; 38: 1–211.

Westergaard

Munksgaard

Bendtsen

et al.

Medication-overuse headache: A perspective review. Ther Adv Drug Saf 2016; 7: 147–158.

Evers

Jensen

. Treatment of medication overuse headache – guideline of the EFNS headache panel. Eur J Neurol 2011; 18: 1115–1121.

Carlsen

Munksgaard

Jensen

et al.

Complete detoxification is the most effective treatment of medication-overuse headache: A randomized controlled open-label trial. Cephalalgia 2018; 38: 225–236.

Tassorelli

Jensen

Allena

et al.

A consensus protocol for the management of medication-overuse headache: Evaluation in a multicentric, multinational study. Cephalalgia 2014; 34: 645–655.

Diener

Holle

Solbach

et al.

Medication-overuse headache: Risk factors, pathophysiology and management. Nat Rev Neurol 2016; 12: 575–583.

Kristoffersen

Lundqvist

. Medication-overuse headache: A review. J Pain Res 2014; 7: 367–378.

Diener

. Detoxification for medication overuse headache is not necessary. Cephalalgia 2012; 32: 423–427.

Bendtsen

Birk

Kasch

et al.

Reference programme: Diagnosis and treatment of headache disorders and facial pain. Danish Headache Society, 2nd Edition, 2012. J Headache Pain 2012; 13: S1–S29.

10.

Munksgaard

Bendtsen

Jensen

. Detoxification of medication-overuse headache by a multidisciplinary treatment programme is highly effective: A comparison of two consecutive treatment methods in an open-label design. Cephalalgia 2012; 32: 834–844.

11.

Olesen

. Detoxification for medication overuse headache is the primary task. Cephalalgia 2012; 32: 420–422.

12.

Benz

Nussle

Lehmann

et al.

Health and quality of life in patients with medication overuse headache syndrome after standardized inpatient rehabilitation: A cross-sectional pilot study. Medicine 2017; 96: 1–7. .

13.

Da Silva

Lake

3rd . Clinical aspects of medication overuse headaches. Headache 2014; 54: 211–217.

14.

Munksgaard

Jensen

. Medication overuse headache. Headache 2014; 54: 1251–1257.

15.

Zebenholzer

Thamer

Wober

. Quality of life, depression, and anxiety 6 months after inpatient withdrawal in patients with medication overuse headache: An observational study. Clin J Pain 2012; 28: 284–290.

16.

Rossi

Faroni

Nappi

. Medication overuse headache: Predictors and rates of relapse in migraine patients with low medical needs. A 1-year prospective study. Cephalalgia 2008; 28: 1196–1200.

17.

Sarchielli

Messina

Cupini

et al.

Sodium valproate in migraine without aura and medication overuse headache: A randomized controlled trial. Eur Neuropsychopharmacol 2014; 24: 1289–1297.

18.

Bendtsen

Munksgaard

Tassorelli

et al.

Disability, anxiety and depression associated with medication-overuse headache can be considerably reduced by detoxification and prophylactic treatment. Results from a multicentre, multinational study (COMOESTAS project). Cephalalgia 2014; 34: 426–433.

19.

Kristoffersen

Straand

Vetvik

et al.

Brief intervention by general practitioners for medication-overuse headache, follow-up after 6 months: A pragmatic cluster-randomised controlled trial. J Neurol 2016; 263: 344–353.

20.

Al Jumah

Al Khathaami

Tamim

et al.

HURT (Headache Under-Response to Treatment) questionnaire in the management of primary headache disorders: Reliability, validity and clinical utility of the Arabic version. J Headache Pain 2013; 14: 16.

21.

Buse

Sollars

Steiner

et al.

Why HURT? A review of clinical instruments for headache management. Curr Pain Headache Rep 2012; 16: 237–254.

22.

Steiner

. Lifting the burden: The global campaign against headache. Lancet Neurol 2004; 3: 204–205.

23.

Steiner

Buse

Al Jumah

et al.

The headache under-response to treatment (HURT) questionnaire, an outcome measure to guide follow-up in primary care: Development, psychometric evaluation and assessment of utility. J Headache Pain 2018; 19: 15.

24.

Westergaard

Steiner

MacGregor

et al.

The Headache Under-Response to Treatment (HURT) Questionnaire: Assessment of utility in headache specialist care. Cephalalgia 2013; 33: 245–255.

25.

Skevington

Lotfy

O'Connell

. The World Health Organization's WHOQOL-BREF quality of life assessment: Psychometric properties and results of the international field trial. A report from the WHOQOL group. Qual Life Res 2004; 13: 299–310.

26.

Schmidt

Muhlan

Power

. The EUROHIS-QOL 8-item index: Psychometric results of a cross-cultural field study. Eur J Public Health 2006; 16: 420–428.

27.

Pires

Fleck

Power

et al.

Psychometric properties of the EUROHIS-QOL 8-item index (WHOQOL-8) in a Brazilian sample. Rev Bras Psiquiatr 2018; 40: 249–255.

28.

Nosikov

Gudex

. EUROHIS - Developing Common Instruments For Health Surveys, 57th edn. Amsterdam: IOS Press, 2003, pp. 145–164.

29.

D'Amico

Grazzi

Bussone

et al.

Are depressive symptomatology, self-efficacy, and perceived social support related to disability and quality of life in patients with chronic migraine associated to medication overuse? Data from a cross-sectional study. Headache 2015; 55: 636–645.

30.

Ayzenberg

Katsarava

Sborowski

et al.

Headache-attributed burden and its impact on productivity and quality of life in Russia: Structured healthcare for headache is urgently needed. Eur J Neurol 2014; 21: 758–765.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.01 MB